Research
Hormonal
Semaglutide (2.4 mg) reduces the risk of major adverse cardiovascular events (MACE) by 20% in patients with cardiovascular disease and obesity, independent of diabetes status.
If you have heart disease and are overweight, Semaglutide may offer a 20% reduction in your risk of heart attack, stroke, or cardiovascular death, in addition to helping with weight loss. This benefit exists even if you do not have diabetes.
StrongSupportsHIGH confidence
Bezüglich harter Endpunkte konnte die SELECT-Studie für schwere unerwünschte kardiovaskuläre Ereignisse (MACE) eine Risikoreduktion von 20 % unter Semaglutid zeigen.
Why this rating
Based on the SELECT study, a large, randomized, double-blind, placebo-controlled trial.
Source
Peptidhormonanaloga basierte medikamentöse Adipositastherapie ist effektiv
M. Azhar Hussain et al. · Die Chirurgie · 2025
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →